ISRCTN35774128已完成不适用
A randomised controlled trial of a 12-month multi-component intervention versus a less intensive version on study participants' maintenance of weight loss
Cardiff University (UK)0 个研究点目标入组 950 人开始时间: 2010年1月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 950
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Obese adults aged 18 - 70 years, either sex
- •2. Current or previous body mass index (BMI) of 30 or above
- •3. Lost at least 5% body weight (by pharmacological, lifestyle and/or behavioural methods) during the last 12 months
- •4. Independent verification of weight loss
排除标准
- •1. Unable to comply with study protocol, e.g., due to mental health problems, terminal illness or competence in English
- •2. Pregnant women
研究者
相似试验
撤回
4 期
Surgery for otitis media in Indigenous Australian childreACTRN12611001073998niversity of Melbourne200
进行中（未招募）
不适用
A 12-week treatment, multi-center, randomized, parallel group, blinded, double dummy study to compare the efficacy and safety of Indacaterol (150 µg o.d.) delivered via a SDDPI with Tiotropium (18 µg o.d.) delivered via a HandiHaler®, in patients with moderate-to-severe COPD.COPD (chronic obstructive pulmonary disease)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-010665-23-FRovartis Pharma Services AG1,568
进行中（未招募）
不适用
A 12-week treatment, multi-center, randomized, parallel group, blinded, double dummy study to compare the efficacy and safety of Indacaterol (150 µg o.d.) delivered via a SDDPI with Tiotropium (18 µg o.d.) delivered via a HandiHaler®, in patients with moderate-to-severe COPD.COPD (chronic obstructive pulmonary disease)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-010665-23-GRovartis Pharma Services AG1,600
进行中（未招募）
不适用
A 12-week treatment, multi-center, randomized, parallel group, blinded, double dummy study to compare the efficacy and safety of Indacaterol (150 µg o.d.) delivered via a SDDPI with Tiotropium (18 µg o.d.) delivered via a HandiHaler®, in patients with moderate-to-severe COPD.COPD (chronic obstructive pulmonary disease)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-010665-23-ATovartis Pharma Services AG1,600
进行中（未招募）
不适用
A 12-week treatment, multi-center, randomized, parallel group, blinded, double dummy study to compare the efficacy and safety of Indacaterol (150 µg o.d.) delivered via a SDDPI with Tiotropium (18 µg o.d.) delivered via a HandiHaler®, in patients with moderate-to-severe COPD.COPD (chronic obstructive pulmonary disease)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-010665-23-DKovartis Pharma Services AG1,600